GlaxoSmithKline Buys Back Into Dermatology With $2.9 Billion Stiefel Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Acquisition more than doubles GSK’s dermatology sales to $1.5 billion, creating a global specialist business across prescription and OTC drugs.